CRY
$17.84
Cryolife
($.77)
(4.14%)
CRY
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.02)
Revenue:  $79.50 Mil
Thursday
Feb 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, November 4, 2021

What do you expect when CRY reports earnings?
Beat
Meet
Miss

Where is CRY's stock price going from here?
Up
Flat
Down
Stock chart of CRY
Analysts
Summary of analysts' recommendations for CRY
Score
Grade
Pivots
Resistance
$20.01
$19.47
$18.66

$18.12

Support
$17.31
$16.77
$15.96
Tweet
Growth
Description
CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife's BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries.
Peers
Edwards LifesciencesIntuitive SurgicalAlign TechnologySTERISInvacareLakeland Industries